Location Symbol Title MIM # Disorder Comments Method Mouse
11q22-q23 API2, HAIP1 Apoptosis inhibitor-2 601721 fused with MALT1 in MALT lymphoma A
11q22-q23 CUL5, VACM1 Cullin-5 (vasopressin-activated calcium-mobilizing receptor-1) 601741 REc
11q22-q23 DDX10 DEAD/H box-10 (RNA helicase) 601235 400kb telomeric to ATM; pseudogene on 9q21-q22; fused with NUP98 inAML REa, Ch
11q22-q23 MMP1, CLG Matrix metalloproteinase 1 (interstitial collagenase) 120353 COPD, rate of decline of lung function in, 606963 (3); Epidermolysisbullosa dystrophica, autosomal recessive, modifier of, 226600 (3) REn
11q22-q24 PPP2R1B Protein phosphatase 2, structural/regulatory subunit A, beta 603113 Lung cancer, 211980 (3) REc, R
11q22-q24 TECTA, DFNA8, DFNA12, DFNB21 Tectorin, alpha 602574 Deafness, autosomal dominant 8/12, 601543 (3); Deafness, autosomalrecessive 21, 603629 (3) Psh, REc
11q22-qter ANC Anal canal carcinoma 105580 ?Anal canal carcinoma (2) 3p22 also deleted Ch
11q22.3 ATM, ATA, AT1 Ataxia-telangiectasia mutated (includes complementation groups A, C, D, and E) 607585 Ataxia-telangiectasia, 208900 (3); Lymphoma, B-cell non-Hodgkin,somatic (3); {Breast cancer, susceptibility to}, 114480 (3); Lymphoma, mantle cell (3); T-cell prolymphocytic leukemia, sporadic (3) Fd, C, M 9(Atm)
11q22.3 CASP12, CASP12P1 Caspase 12, apoptosis-related cysteine protease 608633 {Sepsis, susceptibility to} (3) REc
You are viewing a mobilized version of this site...
View original page here